1. Home
  2. SER vs NRSN Comparison

SER vs NRSN Comparison

Compare SER & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Serina Therapeutics Inc.

SER

Serina Therapeutics Inc.

HOLD

Current Price

$2.01

Market Cap

29.3M

Sector

Health Care

ML Signal

HOLD

Logo NeuroSense Therapeutics Ltd.

NRSN

NeuroSense Therapeutics Ltd.

HOLD

Current Price

$0.77

Market Cap

26.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SER
NRSN
Founded
2017
2017
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
29.3M
26.4M
IPO Year
2018
2021

Fundamental Metrics

Financial Performance
Metric
SER
NRSN
Price
$2.01
$0.77
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
1
Target Price
$13.00
$14.00
AVG Volume (30 Days)
24.7K
364.9K
Earning Date
11-13-2025
04-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$116,000.00
N/A
Revenue This Year
$134.46
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.71
$0.68
52 Week High
$7.92
$2.60

Technical Indicators

Market Signals
Indicator
SER
NRSN
Relative Strength Index (RSI) 26.75 36.78
Support Level $1.71 $0.68
Resistance Level $2.75 $0.91
Average True Range (ATR) 0.26 0.07
MACD -0.05 -0.01
Stochastic Oscillator 21.77 36.29

Price Performance

Historical Comparison
SER
NRSN

About SER Serina Therapeutics Inc.

Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.

About NRSN NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.

Share on Social Networks: